Cinnagen: Difference between revisions

Content deleted Content added

Inline

Revision as of 14:55, 18 August 2012

CinnaGen is an Iran based biotechnology company, the biggest in the region. It has more than 14 years of experience in manufacturing of molecular biology, biopharmaceuticals and diagnostic products. Founded in 1994, CinnaGen currently manufactures more than 42 products and distributes more than 120 different laboratory diagnostic reagents for in vitro use.

CinnaGen is the oldest biotechnology company in the region with a research and development goal and has gained expertise and extensive experience in the areas of molecular biology, recombinant DNA technology and cell biology as the backbone of their products. In addition, CinnaGen has acted as the research consultant in biotechnology for other manufacturers in the region for development of new products.

In collaboration with the Fraunhofer Institute in Germany Cinnagen developed Cinnovex, which in 2007 became the first biogeneric clone of interferon-beta to be used for treatment of multiple sclerosis when it was approved by the Iranian Food and Drug Administration.^[1]^[2] Other product of CinnaGen are Betapoietin, Buserelin, ReciGen, Cinnafact, and some others. In 2011 Cinnagen started to expand its manufacturing compelex and the new production site is ready for production from early in 2013.

References

^ "Aus Deutschland für Kranke in Iran (From Germany for the sick in Iran)". Wiener Zeitung (in German). 2007-03-20. Retrieved 2008-03-31.
^ "First biogeneric therapeutic protein from Fraunhofer Institute introduced to the market". BioRegio STERN. 2007-01-22. Retrieved 2008-03-31.

External links

CinnaGen official site
CinnoVex official site
ReciGen official site
Growing demand for Iranian MS medicine in world, Mehr News Agency, November 15, 2008.
[1] Sciogen is the UK Distribution channel

[1] "Aus Deutschland für Kranke in Iran (From Germany for the sick in Iran)". Wiener Zeitung (in German). 2007-03-20. Retrieved 2008-03-31.

[2] "First biogeneric therapeutic protein from Fraunhofer Institute introduced to the market". BioRegio STERN. 2007-01-22. Retrieved 2008-03-31.

[1]

[2]

@@ Line 6: / Line 6: @@
 In collaboration with the [[Fraunhofer Institute]] in [[Germany]] Cinnagen developed Cinnovex, which in 2007 became the first [[biogeneric]] [[clone (genetics)|clone]] of [[interferon-beta]] to be used for treatment of [[multiple sclerosis]] when it was approved by the Iranian Food and Drug Administration.<ref>{{cite news |title=Aus Deutschland für Kranke in Iran (From Germany for the sick in Iran) |url=http://www.wienerzeitung.at/DesktopDefault.aspx?TabID=4109&Alias=wzo&cob=275793 |work=[[Wiener Zeitung]] |date=2007-03-20 |accessdate=2008-03-31 |language=German}}</ref><ref>{{cite news |title=First biogeneric therapeutic protein from Fraunhofer Institute introduced to the market |url=http://www.bioregio-stern.de/en/first_biogeneric_therapeutic_protein_from_fraunhofer_institute_introduced_to_the_market |work=BioRegio STERN |date=2007-01-22 |accessdate=2008-03-31 }}</ref>
 Other product of CinnaGen are [[Betapoietin]], [[Buserelin]], [[ReciGen]], [[Cinnafact]], and some others.
+In 2011 Cinnagen started to expand its manufacturing compelex and the new production site is ready for production from early in 2013.
-In 2010, AryoGen Biopharma established in order to expand CinnaGen goals in development of [[biotechnology]] in [[Iran]] and the region. [[AryoGen]] is focusing mostly on production of [[monoclonal antibodies]], although its first introduced product is [[Blood Factor VII]] ([[AryoSeven]]) for treatment of patient with [[hemophilia]] disease.